People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide,

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of insurance-imposed limits that disrupt treatment.

Point32Health will dramatically change how and when it pays for Zepbound — the insurer’s preferred GLP-1 weight-loss drug— when used to treat overweight or obesity.